| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 1.20% |
| NAV | ₹13.45 (31 Jul 2020) |
|---|---|
| Fund Started | 28 Dec 2015 |
| Fund Size | ₹241 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 17.1% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 16.0% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 9.7% |
| Lupin Ltd. | Healthcare | Equity | 8.4% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 6.6% |
| Cipla Ltd. | Healthcare | Equity | 6.1% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 5.6% |
| Procter & Gamble Health Ltd. | Healthcare | Equity | 4.4% |
| Narayana Hrudayalaya Ltd. | Healthcare | Equity | 4.3% |
| Abbott India Ltd. | Healthcare | Equity | 4.2% |
Tata India Pharma & HealthCare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Tata Mutual Fund. This scheme was made available to investors on 28 Dec 2015. Rupesh Patel, Sonam Udasi is the Current Fund Manager of Tata India Pharma & HealthCare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹241 Cr and the Latest NAV as of 31 Jul 2020 is ₹13.45.
The Tata India Pharma & HealthCare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. For units in excess of 12% of the investment,1% will be charged for redemption within 365 Days.
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.